A new wave of pharmaceutical optimism meets the slower rhythm of scientific scrutiny: GLP-1 drugs like semaglutide and tirzepatide demonstrably reduce weight, yet emerging meta-analyses suggest their broader promise — improved quality of life, lasting cardiovascular protection — may be more fragile than early headlines implied. When patients stop taking them, the weight returns at four times the pace of conventional methods, and with it, the very conditions the drugs were meant to address. Medicine is being reminded, once again, that chronic conditions rarely yield to short-term interventions,